RT Journal Article
SR Electronic
T1 SARS-CoV-2 infection induces the production of autoantibodies in severe COVID-19 patients in an age-dependent manner
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.12.04.22282902
DO 10.1101/2022.12.04.22282902
A1 Dennyson Leandro M Fonseca
A1 Igor Salerno Filgueiras
A1 Alexandre HC Marques
A1 Elroy Vojdani
A1 Gilad Halpert
A1 Yuri Ostrinski
A1 Gabriela Crispim Baiocchi
A1 Desirée Rodrigues Plaça
A1 Paula P. Freire
A1 Shahab Zaki Pour
A1 Guido Moll
A1 Rusan Catar
A1 Yael Bublil Lavi
A1 Jonathan I. Silverberg
A1 Jason Zimmerman
A1 Gustavo Cabral de Miranda
A1 Robson F Carvalho
A1 Taj Ali Khan
A1 Harald Heidecke
A1 Rodrigo JS Dalmolin
A1 Andre Ducati Luchessi
A1 Hans D. Ochs
A1 Lena F. Schimke
A1 Howard Amital
A1 Gabriela Riemekasten
A1 Israel Zyskind
A1 Avi Z Rosenberg
A1 Aristo Vojdani
A1 Yehuda Shoenfeld
A1 Otavio Cabral-Marques
YR 2022
UL http://medrxiv.org/content/early/2022/12/05/2022.12.04.22282902.abstract
AB Age is a significant risk factor for the coronavirus disease 2019 (COVID-19) outcomes due to immunosenescence and certain age-dependent medical conditions (e.g., obesity, cardiovascular disorder, diabetes, chronic respiratory disease). However, despite the well-known influence of age on autoantibody biology in health & disease, its impact on the risk of developing severe COVID-19 remains poorly explored. Here, we performed a cross-sectional study of autoantibodies directed against 58 targets associated with autoimmune diseases in 159 individuals with different COVID-19 outcomes (with 71 mild, 61 moderate, and 27 severe patients) and 73 healthy controls. We found that the natural production of autoantibodies increases with age and is exacerbated by SARS-CoV-2 infection, mostly in severe COVID-19 patients. Multivariate regression analysis showed that severe COVID-19 patients have a significant age-associated increase of autoantibody levels against 16 targets (e.g., amyloid β peptide, β catenin, cardiolipin, claudin, enteric nerve, fibulin, insulin receptor a, and platelet glycoprotein). Principal component analysis with spectrum decomposition based on these autoantibodies indicated an age-dependent stratification of severe COVID-19 patients. Random forest analysis ranked autoantibodies targeting cardiolipin, claudin, and platelet glycoprotein as the three most crucial autoantibodies for the stratification of severe elderly COVID-19 patients. Follow-up analysis using binomial regression found that anti-cardiolipin and anti-platelet glycoprotein autoantibodies indicated a significantly increased likelihood of developing a severe COVID-19 phenotype, presenting a synergistic effect on worsening COVID-19 outcomes. These findings provide new key insights to explain why elderly patients less favorable outcomes have than young individuals, suggesting new associations of distinct autoantibody levels with disease severity.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by FAPESP grants 2018/18886-9, 2020/01688-0, and 2020/07069-0 to OCM, 2020/16246-2 to DLMF, 2020/09146-1 to PPF, 2020/07972-1 to GCB, 2020/11710-2 to DRP and CAPESAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:APPROVED BY INTEGREVIEW IRB NOVEMBER 21, 2020I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the supplementary tables